J Cancer 2022; 13(5):1695-1705. doi:10.7150/jca.69574 This issue

Research Paper

Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer

Mandika Chetry2, Adheesh Bhandari3,4✉, Yue Lin1✉

1. Department of Reproductive Medicine Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, China
2. Department of Oncology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
3. Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
4. Department of General Surgery, Breast and Thyroid Unit, Primera Hospital, Kathmandu, Nepal

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chetry M, Bhandari A, Lin Y. Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer. J Cancer 2022; 13(5):1695-1705. doi:10.7150/jca.69574. Available from https://www.jcancer.org/v13p1695.htm

File import instruction

Abstract

Graphic abstract

Background: BET family proteins have a role as epigenetic readers to accelerate the transcription of target genes. Several studies have shown that the BET protein family played important roles in several biological processes. Although, the prognostic influence of individual BET genes family in ovarian cancer patients remains unclear.

Methods: We investigated BET mRNA prognostic roles subtypes in ovarian cancer patients by means of the KM plotter database. The BET mRNA expression and protein in cancer and normal ovarian cells was determined using qRTPCR and western blot. We used the HPA database to look at the protein expression profiles in normal and cancer tissues for this study.

Results: Among BET members, mRNA expression BRD2 showed improve OS in all the ovarian malignancy patients, serous patients, stage III and IV, grade II and grade III, TP53 mutated ovarian cancer patients, as well as all patients treated with Platin based chemotherapy. As for BRD3, we found that BRD3 expression was related to better OS in endometrioid ovarian carcinoma and stage III+IV ovarian carcinoma patients, as well as all patients managed with Taxol and concurrent Taxol+Platin based chemotherapy. In addition, BRDT was associated with better OS in all ovarian carcinoma patients, grade I and grade III, all clinical stage (I+II, III+IV) patients, as well as all patients cured with Taxol and concurrent Taxol+Platin chemotherapy.

Conclusion: We conclude that high expression of BRD2, BRD3, and BRDT predicted a better prognosis. mRNA expression of BET family is considerably associated with the prognosis of ovarian carcinoma and individual BET family gene could act as a predictive prognostic indicator in ovarian carcinoma.

Keywords: Bromodomain and extra-terminal, BET, prognosis, ovarian cancer